Health Professional Radio - Podcast

Dr. Arezou Khosroshahi​, ​MD, Associate Professor of Medicine at Emory University​ discusses the enrollment of the first patient in Horizon Therapeutics' Phase 2 trial to evaluate HZN-7734, ​a first- in-class, fully human monoclonal antibody to treat people with moderate to severely active systemic lupus erythematosus (SLE). SLE is an autoimmune disease where the immune system mistakenly attacks healthy cells and tissues. Of the 5 million people living with a form of lupus, SLE accounts for nearly 70 percent of cases and presents a tremendous unmet treatment need.​ #HorizonTherapeutics #SystemicLupusErythematosus Arezou Khosroshahi is an Associate Professor of Medicine in the division of Rheumatology. She joined Emory in 2012 and founded the IgG4-RD clinic at Emory. This clinic is one of the few in the United States to evaluate and treat patients with IgG4-RD with referral from all around the Southeast. She has been one of the initial investigators interested in understanding IgG4-RD since her fellowship at M